	d Therapies Babilist	a ve principal	(e)				nt. Direction	
	Specifical terms (Chow intuitiberance) Show Beaudifference show a fing therefore the show a fing therefore (Chow intuitiberance)	E E E	Z/Z/   Idd (Videx/didanosine)	Odc (Flivia/Saiciebrie)	Z 2 Od 1 (Ziagen/abacavii)	T III	Use apticul	INTHERAPY REJECTED III. OOOOO NOON INTHERAPY REJECTED III.
	S E Sea	d Disas de Arados	AZT (Retro ddl (Videx/	dat (Filvia/Zaickapine)	Jo41 (ZeitV JABC (Ziago	zincata libibitos (F))		OOOOO CCC
	Area Door	Antiestowes Diago		) (0) (0)		ntoleus		000
			ガッ		717			OO sided but
	heraptes   heraptes			٠.				n v is arm
	Stow I Drag Therapes (C. Stow Hollog Ibberatus)  Rhow 2 Brag Therapes (E. Stow d'Erra Therapes)			76				III
				·				ECTED
		1340	\$33.88 \$28.44	\$38.50 \$40.24	\$38.77 \$28.71			III THERRPY REJECTED III
		That That a	h 15 M 9	h 16 h 14	ਜ ਹਿ			HERR
			48h 412h	<b>출</b> 출	ති සි			
		(i) control eletans	Rilabutin+NFV	Rifabutin+NFV Rifabutin+NFV	Rifabutin+NFV	ublion		
	dn)	AN SAMOLE	2 : Rifal 5	5 Rifa 5 Rifa	7 Rifa 7	ScreenEva		000
TPMS Palient	Heologi History   Madi	1 111	2 5	വവ	សល	See Mare   See All   Optim   C. Fill Screen Evaluation	W.	00000
	T Report	0 of 249		~ >	> >	Ail Trap	11. 141 10	
S Palient	History ale Curen	Навам Ораска (10 of 24) n	Ag ddi, d41, NFV ■ ddi, d41, EFV	A ddl, NFV, EFV A ddl, NFV, EFV	Adc, NPV, EPV	Note   Case	Linean Bern arr Mirwe	
<b>V1PM</b>	Herita Transfer	1 (A) (A) (A)	<b>1 2 3 3 3 3 3 3 3 3 3 3</b>	\$ \$ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	₩ ÷		Therapy	

• Viranune (nevirapine/NVP) Resistance Advisory: According to the last genotype data entered, the patient's virus currently has mutation(s) which is/are associated

with resistance to Viramune. FillMuE, RejectionS4

evidence of the M184V/M1841 mutation which is associated with resistance to 3TC . However, this mutant has increased sensitivity to the antiRetrovir al activity of • Resistance Advisory: According to the last genotype data entered, the patient's virus currently has the following mutations, M1847 [RT]. The genotype test displays AZT and ADV so an AZT/3TC or AZT/ADV combination is still useable. Therefore combinations which contain AZT/3TC and AZT/ADV are shown as therapy options although these therapies have been ranked down +5 in favor of three drug combinations with no resistant mutants. FiltMuB, Rejection51

• Epivir and Viramune Resistance Advisory: The patient's last phenotypic assay demonstrates phenotypic resistance to Epivir and Viramune, therefore, therapies containing Epivir and Viranune are not recommended at this time. FiliResC, Rejection 2

• NVP 🖒: Drug Interaction Alext: Patient is currently taking rifabutin and there is insufficient data to assess whether dose adjustments are necessary. These drugs

